Gilead Sciences, Inc. (NASDAQ:GILD) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned an average rating of “Moderate Buy” from the twenty-nine research firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and twenty-three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $159.81.

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Bank of America lifted their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research note on Thursday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $159.08 on Wednesday. The business has a 50 day moving average of $149.65 and a 200 day moving average of $139.13. Gilead Sciences has a 1-year low of $114.02 and a 1-year high of $160.51.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the company earned $2.01 EPS. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. Equities analysts predict that Gilead Sciences will post -0.48 EPS for the current year.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst commentary suggests Gilead could be substantially undervalued if new oncology trial data validate the company’s pipeline and create a larger long-term growth opportunity. Gilead Stock Could Be 50% Undervalued on New Oncology Trial News
• Positive Sentiment: Gilead reached an agreement with Canada’s pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), improving potential access and commercial prospects for the primary biliary cholangitis treatment. Gilead Reaches Canadian Reimbursement Agreement for LYVDELZI
• Positive Sentiment: An analyst raised the company’s fiscal 2026 EPS forecast, providing a modest fundamental tailwind ahead of earnings. FY2026 EPS Forecast for Gilead Sciences Raised
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide therapies, potentially strengthening the company’s longer-term growth strategy and business-development profile. Gilead Deal Shows Big Pharma Appetite for Oral Peptides
• Neutral Sentiment: Gilead is preparing to report third-quarter results. Strong HIV sales, Yeztugo momentum and oncology developments could support the shares, but analysts also flag competitive pressure. Gilead Q3 Earnings Preview
• Neutral Sentiment: Wall Street’s pre-earnings estimates focus on revenue, earnings and operating metrics for the quarter ended September 2026; the reports offer expectations but do not represent released results. Gilead Q3 Wall Street Estimates
• Negative Sentiment: Exchange-traded funds were reported as net sellers of Gilead shares on October 23, indicating some short-term institutional selling pressure. ETFs Are Net Sellers of Gilead

Insider Transactions at Gilead Sciences

In other news, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the completion of the sale, the chief executive officer owned 577,133 shares of the company’s stock, valued at approximately $85,785,049.12. The trade was a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 111,000 shares of company stock valued at $15,877,860. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc purchased a new stake in Gilead Sciences during the 2nd quarter valued at $1,316,606,000. Deutsche Bank AG bought a new stake in Gilead Sciences in the 2nd quarter worth $918,387,000. Jupiter Topco LLC bought a new stake in Gilead Sciences in the 2nd quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Gilead Sciences in the 2nd quarter worth $398,905,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.